FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294286418> ?p ?o ?g. }

• W4294286418 abstract "Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to colonisation of the lungs with the fungus Aspergillus fumigatus, and affects around 10% of people with cystic fibrosis. ABPA is associated with an accelerated decline in lung function. High doses of corticosteroids are the main treatment for ABPA; although the long-term benefits are not clear, and their many side effects are well-documented. A group of compounds, the azoles, have activity against A fumigatus, and have been proposed as an alternative treatment for ABPA. Of this group, itraconazole is the most active. A separate antifungal compound, amphotericin B, has been used in aerosolised form to treat invasive infection with A fumigatus, and may have potential for the treatment of ABPA. Antifungal therapy for ABPA in cystic fibrosis needs to be evaluated. This is an update of a previously published review.The review aimed to test the hypotheses that antifungal interventions for the treatment of ABPA in cystic fibrosis: 1. improve clinical status compared to placebo or standard therapy (no placebo); and 2. do not have unacceptable adverse effects. If benefit was demonstrated, we planned to assess the optimal type, duration, and dose of antifungal therapy.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals, and abstract books of conference proceedings. Date of the most recent search of the Group's Trials Register was 28 September 2021. We searched ongoing trials registries, most recently on 11 March 2022. Earlier, we also approached pharmaceutical companies regarding possible unpublished trials.Published or unpublished randomised controlled trials, in which antifungal treatments were compared to either placebo or no treatment, or where different doses of the same treatment were used in the treatment of ABPA in people with cystic fibrosis.The searches identified six trials; none of which met the inclusion criteria for the review.We included no completed randomised controlled trials. There is currently one ongoing trial, which we may find eligible for a future update.At present, there are no randomised controlled trials that evaluate the use of antifungal therapies for the treatment of ABPA in people with cystic fibrosis, although one trial is currently ongoing. Trials with clear outcome measures are needed to properly evaluate the use of corticosteroids in people with ABPA and cystic fibrosis." @default.
• W4294286418 created "2022-09-02" @default.
• W4294286418 creator A5049835765 @default.
• W4294286418 creator A5066059636 @default.
• W4294286418 date "2022-09-02" @default.
• W4294286418 modified "2023-09-24" @default.
• W4294286418 title "Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis" @default.
• W4294286418 cites W1821581428 @default.
• W4294286418 cites W1946256898 @default.
• W4294286418 cites W1969971789 @default.
• W4294286418 cites W1974893215 @default.
• W4294286418 cites W1988195179 @default.
• W4294286418 cites W1990490872 @default.
• W4294286418 cites W1997775131 @default.
• W4294286418 cites W1997855218 @default.
• W4294286418 cites W1998979526 @default.
• W4294286418 cites W2005581514 @default.
• W4294286418 cites W2005894108 @default.
• W4294286418 cites W2075425014 @default.
• W4294286418 cites W2077424676 @default.
• W4294286418 cites W2082792877 @default.
• W4294286418 cites W2120902620 @default.
• W4294286418 cites W2122670779 @default.
• W4294286418 cites W2135649656 @default.
• W4294286418 cites W2136496779 @default.
• W4294286418 cites W2142180792 @default.
• W4294286418 cites W2150817537 @default.
• W4294286418 cites W2151891905 @default.
• W4294286418 cites W2153044469 @default.
• W4294286418 cites W2171744559 @default.
• W4294286418 cites W2761997604 @default.
• W4294286418 cites W2887017054 @default.
• W4294286418 cites W2990648940 @default.
• W4294286418 cites W4240236213 @default.
• W4294286418 cites W4241558184 @default.
• W4294286418 cites W4245632000 @default.
• W4294286418 cites W92943117 @default.
• W4294286418 doi "https://doi.org/10.1002/14651858.cd002204.pub5" @default.
• W4294286418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36053129" @default.
• W4294286418 hasPublicationYear "2022" @default.
• W4294286418 type Work @default.
• W4294286418 citedByCount "1" @default.
• W4294286418 countsByYear W42942864182023 @default.
• W4294286418 crossrefType "journal-article" @default.
• W4294286418 hasAuthorship W4294286418A5049835765 @default.
• W4294286418 hasAuthorship W4294286418A5066059636 @default.
• W4294286418 hasConcept C126322002 @default.
• W4294286418 hasConcept C141105273 @default.
• W4294286418 hasConcept C142724271 @default.
• W4294286418 hasConcept C159654299 @default.
• W4294286418 hasConcept C16005928 @default.
• W4294286418 hasConcept C177713679 @default.
• W4294286418 hasConcept C197934379 @default.
• W4294286418 hasConcept C203014093 @default.
• W4294286418 hasConcept C204787440 @default.
• W4294286418 hasConcept C27081682 @default.
• W4294286418 hasConcept C2776391196 @default.
• W4294286418 hasConcept C2776938444 @default.
• W4294286418 hasConcept C2777071850 @default.
• W4294286418 hasConcept C2778871687 @default.
• W4294286418 hasConcept C2779548794 @default.
• W4294286418 hasConcept C2779629538 @default.
• W4294286418 hasConcept C2779787849 @default.
• W4294286418 hasConcept C2780690907 @default.
• W4294286418 hasConcept C71924100 @default.
• W4294286418 hasConceptScore W4294286418C126322002 @default.
• W4294286418 hasConceptScore W4294286418C141105273 @default.
• W4294286418 hasConceptScore W4294286418C142724271 @default.
• W4294286418 hasConceptScore W4294286418C159654299 @default.
• W4294286418 hasConceptScore W4294286418C16005928 @default.
• W4294286418 hasConceptScore W4294286418C177713679 @default.
• W4294286418 hasConceptScore W4294286418C197934379 @default.
• W4294286418 hasConceptScore W4294286418C203014093 @default.
• W4294286418 hasConceptScore W4294286418C204787440 @default.
• W4294286418 hasConceptScore W4294286418C27081682 @default.
• W4294286418 hasConceptScore W4294286418C2776391196 @default.
• W4294286418 hasConceptScore W4294286418C2776938444 @default.
• W4294286418 hasConceptScore W4294286418C2777071850 @default.
• W4294286418 hasConceptScore W4294286418C2778871687 @default.
• W4294286418 hasConceptScore W4294286418C2779548794 @default.
• W4294286418 hasConceptScore W4294286418C2779629538 @default.
• W4294286418 hasConceptScore W4294286418C2779787849 @default.
• W4294286418 hasConceptScore W4294286418C2780690907 @default.
• W4294286418 hasConceptScore W4294286418C71924100 @default.
• W4294286418 hasIssue "9" @default.
• W4294286418 hasLocation W42942864181 @default.
• W4294286418 hasLocation W42942864182 @default.
• W4294286418 hasOpenAccess W4294286418 @default.
• W4294286418 hasPrimaryLocation W42942864181 @default.
• W4294286418 hasRelatedWork W2102326747 @default.
• W4294286418 hasRelatedWork W2115522792 @default.
• W4294286418 hasRelatedWork W2123852339 @default.
• W4294286418 hasRelatedWork W2130565081 @default.
• W4294286418 hasRelatedWork W2156860818 @default.
• W4294286418 hasRelatedWork W2157887645 @default.
• W4294286418 hasRelatedWork W2169858659 @default.
• W4294286418 hasRelatedWork W2374889891 @default.
• W4294286418 hasRelatedWork W4318263015 @default.
• W4294286418 hasRelatedWork W3149065072 @default.
• W4294286418 hasVolume "2022" @default.

• next